Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson’s disease-Reference-Cited by-同舟云学术

Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson’s disease

Published:2009-08-08 Issue:12 Volume:65 Page:1245-1251
ISSN:0031-6970
Container-title:European Journal of Clinical Pharmacology
language:en
Short-container-title:Eur J Clin Pharmacol

Author:

Arbouw Maurits E. L.,Movig Kris L. L.,Egberts Toine C. G.,Poels Petra J. E.,van Vugt Jeroen P. P.,Wessels Judith A. M.,van der Straaten R. J. H. M.,Neef Cees,Guchelaar Henk-Jan

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00228-009-0708-6

Reference11 articles.

1. Rascol O, Brooks DJ, Korczyn AD et al (2006) Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov Disord 21:1844–1850

2. Arbouw ME, Movig KL, Guchelaar HJ et al (2008) Discontinuation of ropinirole and pramipexole in patients with Parkinson's disease: clinical practice versus clinical trials. Eur J Clin Pharmacol 64:1021–1026

3. Neville MJ, Johnstone EC, Walton RT (2004) Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum Mutat 23:540–545

4. Arinami T, Gao M, Hamaguchi H, Toru M (1997) A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet 6:577–582

5. Zappia M, Annesi G, Nicoletti G et al (2005) Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study. Arch Neurol 62:601–605

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An update on the pharmacogenetic considerations when prescribing dopamine receptor agonists for Parkinson’s disease;Expert Opinion on Drug Metabolism & Toxicology;2023-07-03

2. Antipsychotic-Induced Parkinsonism and Dyskinesia in a 43- years Old Male with Schizophrenia: Clinical Case;Personalized Psychiatry and Neurology;2023-05-17

3. A Systematic Review of Parkinson’s Disease Pharmacogenomics: Is There Time for Translation into the Clinics?;International Journal of Molecular Sciences;2021-07-05

4. Atremorine in Parkinson's disease: From dopaminergic neuroprotection to pharmacogenomics;Medicinal Research Reviews;2021-06-09

5. Polymorphisms of Dopamine Receptor Genes and Parkinson’s Disease: Clinical Relevance and Future Perspectives;International Journal of Molecular Sciences;2021-04-06